Olorofim Phase 3 results show fewer kidney complications in patients with invasive aspergillosis
F2G and Shionogi's oral olorofim meets Phase 3 aspergillosis endpoint with fewer kidney adverse events. Explore the results and FDA plans.
Pharma & Biotech
Pharma & Biotech
Shionogi deepens ALS real-world data strategy after $2.5bn Radicava acquisition
Read how Shionogi’s NeuroBANK partnership could shape Radicava evidence, ALS trial design and real-world treatment research.